Search

EVT 201

EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

Triazolam

Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. … Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

MEM 1414

MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed. … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

Methyprylon

Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events. … Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.

Perhexiline

Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.

Povidone K30

A polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See povidone for full details.

Cretostimogene grenadenorepvec

CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. … It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.

OXI-4503

OXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. … In addition, however, preclinical data demonstrates that OXI-4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor infiltrates,

Biochanin A

Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).

Imazaquin